177 related articles for article (PubMed ID: 8851592)
21.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
22. In-vitro susceptibility of clinical isolates of Pseudomonas aeruginosa to beta-lactam and aminoglycoside antibiotics.
Sofianou DC; Vrenas S; Doumboyas J
J Chemother; 1989 Dec; 1(6):391-3. PubMed ID: 2515260
[TBL] [Abstract][Full Text] [Related]
23. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
Weiss K; Lapointe JR
Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
[TBL] [Abstract][Full Text] [Related]
24. Latamoxef in combination with aminoglycosides against Pseudomonas aeruginosa: similarity with ticarcillin.
Sears SD; Tatem BA; Standiford HC
Chemotherapy; 1985; 31(2):102-11. PubMed ID: 3921317
[TBL] [Abstract][Full Text] [Related]
25. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa.
Song W; Woo HJ; Kim JS; Lee KM
Int J Antimicrob Agents; 2003 Jan; 21(1):8-12. PubMed ID: 12507832
[TBL] [Abstract][Full Text] [Related]
27. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Cabezudo I; Pfaller M; Bale M; Wenzel R
Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.
Bassey CM; Baltch AL; Smith RP; Conley PE
Antimicrob Agents Chemother; 1984 Sep; 26(3):417-8. PubMed ID: 6439116
[TBL] [Abstract][Full Text] [Related]
29. [In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
Anan N; Toba S; Ito A; Nakamura R; Tsuji M
Jpn J Antibiot; 2011 Aug; 64(4):203-16. PubMed ID: 22066345
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.
Kurtz TO; Winston DJ; Bruckner DA; Martin WJ
Antimicrob Agents Chemother; 1981 Aug; 20(2):239-43. PubMed ID: 6792982
[TBL] [Abstract][Full Text] [Related]
31. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
32. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
[TBL] [Abstract][Full Text] [Related]
33. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
34. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
Giamarellou H
Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
[TBL] [Abstract][Full Text] [Related]
35. Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Khalil H; Chen T; Riffon R; Wang R; Wang Z
Antimicrob Agents Chemother; 2008 May; 52(5):1635-41. PubMed ID: 18285485
[TBL] [Abstract][Full Text] [Related]
36. Effect of highly potent antipseudomonal beta-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa.
Lerner SA; Dudek EJ; Boisvert WE; Berndt KD
Rev Infect Dis; 1984; 6 Suppl 3():S678-88. PubMed ID: 6443769
[TBL] [Abstract][Full Text] [Related]
37. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
38. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
39. [In vitro sensitivity at 18 antibiotics of 192 strains of Pseudomonas aeruginosa isolated at Garches Hospital].
Ronco E; Vacheron F; Orabona A
Pathol Biol (Paris); 1987 May; 35(5):558-62. PubMed ID: 3112708
[TBL] [Abstract][Full Text] [Related]
40. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
